Bendamustine plus rituximab for the treatment of Waldenström Macroglobulinemia: Patient outcomes and impact of bendamustine dosing

Bendamustine and rituximab (BR) therapy is commonly used in the treatment of Waldenström Macroglobulinemia (WM). The impact dose of Bendamustine dose on response and survival outcomes is not well‐established, and the impact of its use in different treatment settings is not clear. We aimed to report...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:American journal of hematology 2023-05, Vol.98 (5), p.750-759
Hauptverfasser: Arulogun, Suzanne O., Brian, Duncan, Goradia, Harshita, Cooney, Aaron, Menne, Tobias, Koo, RayMun, O'Neill, Aideen T., Vos, Josephine M. I., Pratt, Guy, Turner, Deborah, Marshall, Kirsty, Manos, Kate, Anderson, Claire, Gavriatopoulou, Maria, Kyriakou, Charalampia, Kersten, Marie J., Minnema, Monique C., Koutoumanou, Eirini, El‐Sharkawi, Dima, Linton, Kim, Talaulikar, Dipti, McCarthy, Helen, Bishton, Mark, Follows, George, Wechalekar, Ashutosh, D'Sa, Shirley P.
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!